All publications

References : 1st Sept 2011

Individual references can be found by using the search option.

  1. Verdel BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HG, Egberts TC. Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther. 2011;89(1):89-96.
  2. van Herk-Sukel MP, Shantakumar S, Kamphuisen PW, Penning-van Beest FJ, Herings RM. Myocardial infarction, ischaemic stroke and pulmonary embolism before and after breast cancer hospitalisation. A population-based study. Thromb Haemost. 2011;106(1).
  3. Trifiro G, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, et al. EU-ADR Healthcare Database Network vs. Spontaneous Reporting System Database: Preliminary Comparison of Signal Detection. Stud Health Technol Inform. 2011;166:25-30.
  4. Risselada R, Straatman H, van Kooten F, Dippel DW, van der Lugt A, Niessen WJ, et al. Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage. J Thromb Haemost. 2011;9(3):517-23.
  5. Refoios Camejo R, McGrath C, Herings R. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness. Health Policy. 2011;100(1):18-24.
  6. Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(3):903-10.
  7. Penning-van Beest FJA, van Herk-Sukel MP, Gale R, Lammers JW, Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: A database analysis. Respir Med. 2011;105(2):259-65.
  8. Penning-van Beest FJ, Overbeek JA, Smulders M, van Spiegel PI, Meerding WJ, Herings RM. Evaluation of smoking cessation drug use and outcomes in the Netherlands. J Med Econ. 2011;14(1):124-9.
  9. Penning-van Beest FJ, Overbeek JA, Meijer WM, Woodruff K, Jackson J, Vis H, et al. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes. Pharmacoepidemiol Drug Saf. 2011;20:972-8.
  10. Landis SH, El-Hariry IA, van Herk-Sukel MP, van den Haak P, Janssen-Heijnen ML, Penning-van Beest FJ, et al. Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck. Head Neck. 2011:in press.
  11. Hodgkins P, Sasane R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther. 2011;33(2):188-203.
  12. Herk-Sukel MP, Lemmens VE, Poll-Franse LV, Herings RM, Coebergh JW. Record linkage for pharmacoepidemiological studies in cancer patients. Pharmacoepidemiol Drug Saf. 2011. Epub 2011/08/04.
  13. Geers HC, Bouvy ML, Heerdink ER. Estimates of statin discontinuation rates are influenced by exposure and outcome definitions. Ann Pharmacother. 2011;45(5):576-81.
  14. de Peuter OR, Souverein PC, Klungel OH, Buller HR, de Boer A, Kamphuisen PW. Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure. Eur J Heart Fail. 2011;13(2):220-6.
  15. Czernichow S, Knol MJ, Fezeu L, Grobbee DE. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study. Eur J Cardiovasc Prev Rehabil. 2011:in press.
  16. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20(1):1-11.
  17. Biere-Rafi S, Di Nisio M, Gerdes V, Porreca E, Souverein P, Boer A, et al. Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2011:in press.
  18. Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(7):2197-204.
  19. Arbouw ME, Movig KL, Guchelaar HJ, Neef C, Egberts TC. Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study. Eur J Clin Pharmacol. 2011.
  20. Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone. 2010;47(3):604-9.
  21. Velthove KJ, Souverein PC, van Solinge WW, Leufkens HG, Lammers JW. Effects of corticosteroid use on readmission in obstructive lung disease. Respir Med. 2010;104(2):211-8.
  22. Velthove KJ, Souverein PC, van Solinge WW, Leufkens HG, Lammers JW. Measuring exacerbations in obstructive lung disease. Pharmacoepidemiol Drug Saf. 2010;19(4):367-74.
  23. Velthove KJ, Leufkens HG, Schweizer RC, van Solinge WW, Souverein PC. Medication changes prior to hospitalization for obstructive lung disease: a case-crossover study. Ann Pharmacother. 2010;44(2):267-73.
  24. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010;122(3):843-51.
  25. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, Coebergh JW, et al. New opportunities for drug outcomes research in cancer patients: The linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer. 2010;46:395-404.
  26. van den Haak P, Heintjes E, Plat AW, Jan Meerding W, Webb K, Sturkenboom MC, et al. Determination of non-treatment with statins of high risk patients in The Netherlands. Curr Med Res Opin. 2010;26(2):271-8.
  27. Valkhoff VE, t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2010;33(1):77-88.
  28. Sasane R, Hodgkins P, Meijer W. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Curr Med Res Opin. 2010;26(11):2565-74.
  29. Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG, et al. Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J Clin Endocrinol Metab. 2010;95(4):1924-31.
  30. Peters BJ, Rodin AS, Klungel OH, Stricker BH, de Boer A, Maitland-van der Zee AH. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenet Genomics. 2010;20(12):766-74.
  31. Penning-van Beest FJ, van den Haak P, Klok RM, Prevoo YF, van der Peet DL, Herings RM. Quality of life in relation to constipation among opioid users. J Med Econ. 2010;13(1):129-35.
  32. Milder IE, Klungel OH, Mantel-Teeuwisse AK, Verschuren WM, Bemelmans WJ. Relation between body mass index, physical inactivity and use of prescription drugs: the Doetinchem Cohort Study. Int J Obes (Lond). 2010;34(6):1060-9.
  33. McAfee AT, Rodriguez LA, Goettsch WG, Gonzalez-Perez A, Johansson S, Ming EE, et al. Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries. Minerva Cardioangiol. 2010;58(6):611-22.
  34. Kroger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. Drugs Aging. 2010;27(8):663-75.
  35. Kleijer BC, Heerdink ER, Egberts TC, Jansen PA, van Marum RJ. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol. 2010;30(5):526-30.
  36. Heintjes EM, Thomsen TL, Penning-van Beest FJ, Christensen TE, Herings RM. Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Adv Ther. 2010;27(4):211-22.
  37. Garcia Rodriguez LA, Herings R, Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. Pharmacoepidemiol Drug Saf. 2010;19(12):1218-24.
  38. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, et al. Reply to R. Ferraldeschi et al. J Clin Oncol. 2010.
  39. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, et al. Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer. J Clin Oncol. 2010(28):2423-9.
  40. Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary. 2010;13(3):195-8.
  41. de Peuter OR, Lip GY, Souverein PC, Klungel OH, de Boer A, Buller HR, et al. Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. Eur J Heart Fail. 2010:in press.
  42. Wakkee M, Meijer W, Neumann HA, Herings RM, Nijsten T. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. Acta Derm Venereol. 2009;89(5):476-83.
  43. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2009;130(4):962-7.
  44. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Stricker BH, Kroon AA, de Leeuw PW, et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci. 2009;31(2):158-64.
  45. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, et al. Reasons for non-response in observational pharmacogenetic research. Pharmacoepidemiol Drug Saf. 2009;18(8):665-71.
  46. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, et al. Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. J Hypertens. 2009;27(1):61-8.
  47. van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2009;68(5):668-73.
  48. van der Linden MW, Plat AW, Erkens JA, Emneus M, Herings RM. Large Impact of Antidiabetic Drug Treatment and Hospitalizations on Economic Burden of Diabetes Mellitus in The Netherlands during 2000 to 2004. Value Health. 2009:909-14.
  49. van der Linden MW, Penning-van Beest FJ, Nijsten T, Herings RM. Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands. Drug Saf. 2009;32(6):527-37.
  50. van der Linden MW, Gaugris S, Kuipers EJ, van Herk-Sukel MP, van den Bemt BJ, Sen SS, et al. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiol Drug Saf. 2009;18(10):880-90.
  51. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin. 2009;25(1):195-204.
  52. van den Brand MW, Samson MM, Pouwels S, van Staa TP, Thio B, Cooper C, et al. Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int. 2009;20(10):1705-13.
  53. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(2 Suppl):S3-13.
  54. Risselada R, Straatman H, van Kooten F, Dippel DW, van der Lugt A, Niessen WJ, et al. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke. 2009;40(8):2887-92.
  55. Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2009;20(9):1499-506.
  56. Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T, et al. Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke. 2009;40(10):3281-5.
  57. Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R. Change of initial oral antidiabetic therapy in type 2 diabetic patients. Pharm World Sci. 2009;31(6):622-6.
  58. Meijer WM, Faber A, van den Ban E, Tobi H. Current issues around the pharmacotherapy of ADHD in children and adults. Pharm World Sci. 2009;31(5):509-16.
  59. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy. Melanoma Res. 2009;19(5):327-32.
  60. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol. 2009;20(2):358-64.
  61. Koomen ER, Herings RM, Guchelaar HJ, Nijsten T. Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cancer Epidemiol. 2009;33(5):391-5.
  62. Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94(8):2729-34.
  63. Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol. 2009;129(11):2620-7.
  64. Heintjes EM, Penning-van Beest FJ, Johansson S, Stalenhoef AF, Herings RM. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Curr Med Res Opin. 2009;25(11):2621-9.
  65. Gardarsdottir H, van Geffen EC, Stolker JJ, Egberts TC, Heerdink ER. Does the length of the first antidepressant treatment episode influence risk and time to a second episode? J Clin Psychopharmacol. 2009;29(1):69-72.
  66. Avillach P, Mougin F, Joubert M, Thiessard F, Pariente A, Dufour JC, et al. A Semantic Approach for the Homogeneous Identification of Events in Eight Patient Databases: A Contribution to the European eu-ADR Project. Stud Health Technol Inform. 2009;150:190-4.
  67. Wedzicha JA. Antibiotics at COPD exacerbations: the debate continues. Thorax. 2008;63(11):940-2.
  68. van Wijk BL, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 2008;26(1):145-53.
  69. Sukel MP, van der Linden MW, Chen C, Erkens JA, Herings RM. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiol Drug Saf. 2008;17(1):9-19.
  70. Sukel MP, van de Poll-Franse LV, Nieuwenhuijzen GA, Vreugdenhil G, Herings RM, Coebergh JW, et al. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer. 2008:1846-854.
  71. Sukel MP, Breekveldt-Postma NS, Erkens JA, van der Linden PD, Beiderbeck AB, Coebergh JW, et al. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice. Pharmacoepidemiol Drug Saf. 2008;17(2):125-34.
  72. Stuffken R, Heerdink ER, de Koning FH, Souverein PC, Egberts AC. Association Between Hospitalization and Discontinuity of Medication Therapy Used in the Community Setting in the Netherlands (July/August). Ann Pharmacother. 2008;42(July/August 2008):933-9.
  73. Schneeberger C, Stolk RP, Devries JH, Schneeberger PM, Herings RM, Geerlings SE. Differences in the pattern of antibiotic prescription profile and recurrence rate for possible urinary tract infections in women with and without diabetes. Diabetes Care. 2008;31(7):1380-5.
  74. Roede BM, Bresser P, Bindels PJ, Kok A, Prins M, ter Riet G, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax. 2008;63(11):968-73.
  75. Peters BJ, Maitland-van der Zee AH, Stricker BH, van Wieren-de Wijer DB, de Boer A, Kroon AA, et al. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenet Genomics. 2008;18(7):631-6.
  76. Penning-van Beest FJA, van der Bij S, Erkens JA, Kessabi S, Groot M, Herings RM. Effect on non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin. 2008;24(9):2523-9.
  77. Penning-van Beest FJ, Wolffenbuttel BH, Herings RM. Haemoglobin A(1)(c) Goal Attainment in Relation to Dose in Patients with Diabetes Mellitus Taking Metformin : A Nested, Case-Control Study. Clin Drug Investig. 2008;28(8):487-93.
  78. Penning-van Beest FJ, Koerselman J, Herings RM. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. J Thromb Haemost. 2008;6(2):284-90.
  79. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008;24(5):1337-44.
  80. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19(4):511-7.
  81. Meijer WM, Beest FJ, Olson M, Herings RM. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin. 2008;24(11):3217-22.
  82. Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):661-6.
  83. Knol MJ, Derijks HJ, Geerlings MI, Heerdink ER, Souverein PC, Gorter KJ, et al. Influence of antidepressants on glycaemic control in patients with diabetes mellitus. Pharmacoepidemiol Drug Saf. 2008;17(6):577-86.
  84. Heintjes EM, Hirsch MW, Van der Linden MW, O'Donnell JC, Stalenhoef AF, Herings RMC. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results. Curr Med Res Opin. 2008;24(8):2241-50
  85. Derijks HJ, Heerdink ER, De Koning FH, Janknegt R, Klungel OH, Egberts AC. The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control study. Pharmacoepidemiol Drug Saf. 2008;17(4):336-44.
  86. de Vries F, Pouwels S, Bracke M, Lammers JW, Leufkens H, Klungel O, et al. Use of inhaled corticosteroids and the risk of non-fatal acute myocardial infarction. J Hypertens. 2008;26(1):124-9.
  87. de Vries F, Pouwels S, Bracke M, Lammers JW, Klungel O, Leufkens H, et al. Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol. 2008;65(4):580-6.
  88. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Koerselman J, Klungel OH, Falvey H, et al. Effect of persistent use of antihypertensives on blood pressure goal attainment. Curr Med Res Opin. 2008;24(4):1025-31.
  89. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24(1):121-7.
  90. Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JW, Herings RM. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf. 2008;17(4):411-22.
  91. Breekveldt-Postma NS, Erkens JA, Aalbers R, van de Ven MJ, Lammers JW, Herings RM. Extent of uncontrolled disease and associated medical costs in severe asthma--a PHARMO study. Curr Med Res Opin. 2008;24(4):975-83.
  92. Van Wijk BLG, Avorn J, Solomon DH, Klungel OH, Heerdink ER, De Boer A, et al. Herstarten van antihypertensiva. Pharm Weekbld [Dutch]2007. p. 118-20.
  93. van Wijk BL, Avorn J, Solomon DH, Klungel OH, Heerdink ER, de Boer A, et al. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. J Hypertens. 2007;25(3):689-97.
  94. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Effect of drug combinations on admission for recurrent myocardial infarction. Heart. 2007;93(10):1226-30.
  95. Siiskonen SJ, Breekveldt-Postma NS, Vincze G, Khan ZM, Erkens JA, Herings RM. Higher persistence with valsartan compared with enalapril in daily practice. Vasc Health Risk Manag. 2007;3(6):1039-44.
  96. Penning-van Beest FJA, Herings RMC. Generiek omeprazol als eerstekeuze-PPI: beleid versus praktijk. Modern Medicine. 2007;31(4):163-4.
  97. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007;28(2):154-9.
  98. Penning-van Beest FJ, Koerselman J, Herings RM. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci. 2007;29(6):671-5.
  99. Menckeberg TT, Belitser SV, Bouvy ML, Bracke M, Lammers JW, Raaijmakers JA, et al. Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistence. BMC Health Serv Res. 2007;7:106.
  100. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer. 2007;43(17):2580-9.
  101. Koomen ER, Joosse A, Herings R, Casparie MK, Bergman W, Nijsten T, et al. Effecten van statines op huidmelanomen. Pharm Weekbld [Dutch]2007. p. 133-7.
  102. Knol MJ, Geerlings MI, Egberts AC, Gorter KJ, Grobbee DE, Heerdink ER. No increased incidence of diabetes in antidepressant users. Int Clin Psychopharmacol. 2007;22(6):382-6.
  103. Klein D, Strom BL, Wang P, Cunningham F, Herings RMC, O'Brien CP. The future of postmarketing surveillance of psychotropic medications. CNS Spectr. 2007;12(9 (suppl. 16)):1-20.
  104. Handoko KB, Zwart-van Rijkom JE, Hermens WA, Souverein PC, Egberts TC. Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study. Pharmacoepidemiol Drug Saf. 2007;16(2):189-96.
  105. Gumbs PD, Verschuren WM, Souverein PC, Mantel-Teeuwisse AK, de Wit GA, de Boer A, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol. 2007;64(5):680-5.
  106. Goettsch WG, Sukel MP, van der Peet DL, van Riemsdijk MM, Herings RM. In-hospital use of opioids increases rate of coded postoperative paralytic ileus. Pharmacoepidemiol Drug Saf. 2007;16(6):668-74.
  107. Goettsch WG, de Jong RB, Kramarz P, Herings RM. Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study. Pharmacoepidemiol Drug Saf. 2007;16(2):166-72.
  108. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early Evidence on the Effects of Regulators' Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents. Am J Psychiatry. 2007;164(9):1356-63.
  109. Engels FK, de Jong FA, Mathijssen RH, Erkens JA, Herings RM, Verweij J. Medicinal cannabis in oncology. Eur J Cancer. 2007;43(18):2638-44.
  110. Drabbe NRG, Van Dijk EA, De Visser AC, Van de Linden PD. Verhoogde lactaatspiegels in relatie tot metforminegebuik, nierfunctie, leverfunctie en leukocytenaantal. Pharm Weekbld [Dutch]2007. p. 114-7.
  111. de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP. Use of beta-Blockers and the Risk of Hip/Femur Fracture in the United Kingdom and The Netherlands. Calcif Tissue Int. 2007;80(2):69-75.
  112. de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med. 2007;261(2):170-7.
  113. de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, et al. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2007;16(6):612-9.
  114. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101(7):1398-405.
  115. Bozkurt O, de Boer A, Grobbee DE, Heerdink ER, Burger H, Klungel OH. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol Diagn Ther. 2007;11(5):291-302.
  116. Arbouw ME, Movig KL, Neef C, Guchelaar HJ, Egberts TC. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. Eur J Clin Pharmacol. 2007;63(2):181-7.
  117. Wammes-van der Heijden EA, Rahimtoola H, Leufkens HG, Tijssen CC, Egberts AC. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology. 2006;67(7):1128-34.
  118. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol. 2006;59(1):11-7.
  119. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006.
  120. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother. 2006;40(1):15-20.
  121. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Improving pharmacotherapy after myocardial infarction by group academic detailing using feedback data on a patient level. Pharmacotherapy. 2006;26(2):254-9.
  122. van den Boogaard CHA, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RMC. Persistent biphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin. 2006;22(9):1757-64.
  123. van de Garde EM, Souverein PC, van den Bosch JM, Deneer VH, Leufkens HG. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J. 2006;27(6):1217-22.
  124. ten Berg MJ, Huisman A, Souverein PC, Schobben AF, Egberts AC, van Solinge WW, et al. Drug-induced thrombocytopenia: a population study. Drug Saf. 2006;29(8):713-21.
  125. ten Berg MJ, Goettsch WG, van den Boom G, Smout AJ, Herings RM. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol. 2006;18(5):475-81.
  126. Stricker BH, Herings RM. Pleidooi voor het behoud van de Landelijke Medische Registratie voor betrouwbare informatie over de volksgezondheid en de gezondheidszorg. Ned Tijdschr Geneeskd. 2006;150(35):1916-7.
  127. Storimans MJ, Klungel OH, Talsma H, de Blaey CJ. Regional Influences on the Dispensing of Glucose Test Strips in Dutch Community Pharmacies. Pharm World Sci. 2006;28(1):26-32.
  128. Penning-van Beest FJA, Goettsch W, Erkens JA, Herings RMC. Persistentie van gebruik van bisfosfonaten: cohortstudie naar determinanten bij vrouwen met postmenopauzale osteoporose. Modern Medicine. 2006:80-4.
  129. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236-42.
  130. Penning-van Beest F, Herings RMC. Beter minder vaak en hoger doseren. Pharm Weekbld [Dutch]2006. p. 816-7.
  131. Jong de RB, Goettsch WG, Herings RMC. Klinisch falen doet kosten stijgen. Pharm Weekbld [Dutch]2006. p. 1592-3.
  132. Johansson S, E.E. M, M.A. W, L.A. R, Herings RM, Goettsch W, et al. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiol Drug Saf. 2006;15(7):454-61.
  133. Houben MP, Herings RMC. Glioom niet door antihypertensiva. Pharm Weekbld [Dutch]2006. p. 574-5.
  134. Houben MP, Coebergh JW, Herings RM, Casparie MK, Tijssen CC, van Duijn CM, et al. The association between antihypertensive drugs and glioma. Br J Cancer. 2006;94(5):752-6.
  135. Herings RMC, van den Boogaard CH. Statines veiliger dan gedacht. Pharm Weekbld [Dutch]2006. p. 1066-7.
  136. Herings RMC, Boogaard vdC, Erkens JA. Inzicht ontbreekt in gevolgen substitutie. Pharm Weekblad. 2006;8.
  137. Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Herings RM. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf. 2006;15(7):435-43.
  138. Goettsch W, Bouwes Bavinck J, Herings R. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol. 2006;20(7):834-9.
  139. Gardarsdottir H, Heerdink ER, Egberts AC. Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiol Drug Saf. 2006;15(5):338-43.
  140. Dubbeldam S, Herings RMC. Blijven slikken voorkomt botbreuken. Pharm Weekbld [Dutch]2006. p. 1326-7.
  141. Breekveldt-Postma NS, Siiskonen S, Goettsch W, Herings RMC. Vier op de vijf trouw aan imatinib. Pharm Weekbld [Dutch]2006. p. 550-1.
  142. Veiligheid van rosuvastatine vergelijkbaar met die van andere statinen. Modern Medicine. 2006;9:441.
  143. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23(11):2101-7.
  144. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis. Clin Ther. 2005;27(11):1806-14.
  145. Sturkenboom MC, Goettsch WG, Picelli G, in 't Veld B, Yin DD, de Jong RB, et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol. 2005;60(4):438-43.
  146. Stuffken R, van Hulten RP, Heerdink ER, Movig KL, Egberts AC. The impact of hospitalisation on the initiation and long-term use of benzodiazepines. Eur J Clin Pharmacol. 2005;61(4):291-5.
  147. Penning-van Beest FJA, Sturkenboom MC, Wijk van MAM, Herings RMC. Behandeling van urine-incontinentie in de dagelijkse praktijk. Modern Medicine. 2005(2):85-8.
  148. Penning-van Beest FJ, Sturkenboom MC, Bemelmans BL, Herings RM. Undertreatment of urinary incontinence in general practice. Ann Pharmacother. 2005;39(1):17-21.
  149. Penning-van Beest FJ, Goettsch WG, Herings RMC. Onderbehandeling na fractuur. Pharm Weekbld [Dutch]. 2005(22):751.
  150. Penning-van Beest F, Herings RMC. Onderzoeksprogramma beoordeelt praktijkwaarde innovatie. Pharm Weekbld [Dutch]. 2005(42):1326.
  151. Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol. 2005;61(5-6):439-44.
  152. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Langdurig gebruik van antidepressiva in Nederland in 1991-2001: prevalentie, incidentie en risico-indicatoren. Ned Tijdschr Geneeskd. 2005;149(13):708-11.
  153. Mantel-Teeuwisse AK, Klungel OH, Schalekamp T, Verschuren WM, Porsius AJ, de Boer A. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol. 2005;60(1):83-9.
  154. Herings RMC, Erkens JA, Berg tMJ. Farmacotherapie gesubstitueerd: Een onderzoek naar de gevolgen van verlaging van GVS-limieten op bijbetaling en de gevolgen van generieke en therapeutische substitutie. Utrecht: PHARMO Institute, 2005 ISBN 90-806976-5-7.
  155. Goettsch WG, Termorshuizen F, Herings RMC. Statinen onvoldoende effectief. Pharm Weekbld [Dutch]. 2005;24:814-5.
  156. Goettsch WG, S.D. B, N. B-P, Casparie M, Herings RM, P.C. H. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41(18):2868-72.
  157. Goettsch WG, Jong de R, Herings RMC. Driedaagse kuren nitrofurantoine. Pharm Weekbld [Dutch]2005. p. 508.
  158. Erkens JA, van der Bij S, Herings RMC. Geslacht en type geneesmiddel beinvloeden persistentie bij antihypertensiva. Pharm Weekbld [Dutch]. 2005(50):1600-2.
  159. Erkens JA, Panneman MM, Klungel OH, Boom GV, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14(11):795-803.
  160. Erkens JA, Janse AF, Herings RM. Limited use of medicinal cannabis but for labeled indications after legalization. Pharmacoepidemiol Drug Saf. 2005;14(11):821-2.
  161. De Bruin ML, van Hemel NM, Leufkens HG, Hoes AW. Hospital discharge diagnoses of ventricular arrhythmias and cardiac arrest were useful for epidemiologic research. J Clin Epidemiol. 2005;58(12):1325-9.
  162. Breekveldt-Postma NS, Schillevoort I, Nolen WA, Veraart CP, Herings RM. Selective prescribing of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2005;14(1):25-30.
  163. Breekveldt-Postma NS, Penning-van Beest FJA, Lammers J-W, Herings RMC. Astmabehandeling in de praktijk moeilijk vol te houden. Modern Medicine. 2005(5):36-9.
  164. Breekveldt-Postma NS, Penning-van Beest FJ, Herings RMC. Utilisation pattern of fentanyl transdermal system in The Netherlands. Pharmacoepidemiol Drug Saf. 2005;14(2):129-34.
  165. Breekveldt-Postma NS, Herings RMC. Betere therapietrouw bij specifieke toedieningsvormen nifedipine. Pharm Weekbld [Dutch]. 2005;34:1048.
  166. Breekveldt-Postma NS, Herings RM. Persistence with antihypertensives related to formulation: the case of nifedipine. Ann Pharmacother. 2005;39(2):237-42.
  167. Bouvy ML, Cusell-Borgh M, Herings RMC. Maagprotectie: te veel of te weinig. Pharm Weekbld [Dutch]. 2005(17):570-3.
  168. Van Wijk BL, Klungel OH, Heerdink ER, De Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens. 2004;22(9):1831-7.
  169. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment? Pharm World Sci. 2004;26(5):277-81.
  170. Storimans MJ, Talsma H, Klungel OH, de Blaey CJ. Dispensing glucose test materials in Dutch community pharmacies. Pharm World Sci. 2004;26(1):52-5.
  171. Spoelstra JA, Stolk RP, Klungel OH, Erkens JA, Rutten GE, Leufkens HG, et al. Initiation of glucose-lowering therapy in Type 2 diabetes mellitus patients in general practice. Diabet Med. 2004;21(8):896-900.
  172. Spoelstra JA, Stolk RP, Cohen D, Klungel OH, Erkens JA, Leufkens HG, et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry. 2004;65(5):674-8.
  173. PHARMO. Farmacotherapie tegen elke prijs ? Utrecht: PHARMO Instituut; 2004 Februari 2000. 48 p.
  174. PHARMO. Opioid use and paralytic ilues in the Netherlands. IR. Utrecht: PHARMO Institute, 2004 December 2004. Report No.: P163.
  175. Penning-van Beest FJA, Sturkenboom MCJM, Herings RMC. Behandelingskosten urine-incontinentie blijven maar stijgen. Pharm Weekbld [Dutch]. 2004(50):1684-6.
  176. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004;15(2):120-4.
  177. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004;164(21):2367-70.
  178. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol. 2004;60(1):57-61.
  179. Mantel-Teeuwisse AK, Klungel OH, Egberts TC, Verschuren WM, Porsius AJ, de Boer A. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Saf. 2004;27(1):63-70.
  180. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart. 2004;90(9):1065-6.
  181. Hugtenburg JG, Heerdink ER, Egberts AC. Increased psychotropic drug consumption by children in the Netherlands during 1995-2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2004;60(5):377-9.
  182. Herings RMC. 75.000 patienten lopen substantieel risico. Pharm Weekbld [Dutch]. 2004;139(37):1196-7.
  183. Herings RM, Goettsch WG. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother. 2004;38(5):760-3.
  184. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388-94.
  185. Goettsch WG, Yin DD, Alemao E, Klungel OH, Stalenhoef AF, Herings RM. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin. 2004;20(7):1025-33.
  186. Goettsch WG, van den Boom G, Breekveldt-Postma NS, Smout AJ, Herings RM. Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study. Pharmacoepidemiol Drug Saf. 2004;13(11):803-10.
  187. Goettsch WG, Janknegt R, Herings RM. Increased treatment failure after 3-days' courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database. Br J Clin Pharmacol. 2004;58(2):184-9.
  188. Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. Pharmacoepidemiol Drug Saf. 2004;13(3):139-46.
  189. Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RMC. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med. 2004;98(8):752-9.
  190. Zwart-van Rijkom JE, Breekveldt-Postma NS, Leufkens HG, Egberts AC. Diffusion of new medicines into hospital practice. Eur J Clin Pharmacol. 2003;59(5-6):495-6.
  191. van Staa TP, Cooper C, Leufkens HG, Lammers JW, Suissa S. The use of inhaled corticosteroids in the United Kingdom and the Netherlands. Respir Med. 2003;97(5):578-85.
  192. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163(15):1801-7.
  193. van der Elst ME, Cisneros-Gonzalez N, de Blaey CJ, Buurma H, de Boer A. Oral antithrombotic use among myocardial infarction patients. Ann Pharmacother. 2003;37(1):143-6.
  194. Spoelstra JA, Stolk RP, Heerdink ER, Klungel OH, Erkens JA, Leufkens HG, et al. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiol Drug Saf. 2003;12(2):121-7.
  195. Souverein PC, Erkens JA, de la Rosette JJ, Leufkens HG, Herings RM. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol. 2003;43(5):528-34.
  196. Schoofs MW, van der Klift M, Hofman A, de Laet CE, Herings RM, Stijnen T, et al. Thiazide diuretics and the risk for hip fracture. Annals of internal medicine. 2003;139(6):476-82.
  197. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Incidence and determinants of antidepressant drug use in migraine patients. Int Clin Psychopharmacol. 2003;18(6):331-9.
  198. Panneman MJ, Goettsch WG, Kramarz P, Herings RM. The costs of benzodiazepine-associated hospital-treated fall Injuries in the EU: a Pharmo study. Drugs Aging. 2003;20(11):833-9.
  199. Lingen M. De therapieduur bewaken: gebrekkige therapietrouw geeft dramatisch effect-
  200. en investeringsverlies. Pharm Weekblad. 2003:455.
  201. Herings RMC. PHARMO Instituut koppelt in het belang van de patiënt. Pharm Weekblad. 2003;138(49):1742-5.
  202. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423-4.
  203. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):795-8.
  204. Gerrits C, Herings R, Leufkens H, Lammers J-W. N-acetylcysteine is unlikely to reduce hospitalisation for chronic obstructive pulmonary disease [Letter]. Eur Respir J. 2003;22:865-6.
  205. Erkens J, Klungel O, Stolk R, Grobbee D, Leufkens H. Belaagd aan alle zijden: Multifactoriële behandeling van diabetes mellitus type 2. Pharm Weekblad. 2003;2003(138):1574-9.
  206. De Bruin ML, Hoes AW, Leufkens HG. QTc-prolonging drugs and hospitalizations for cardiac arrhythmias. Am J Cardiol. 2003;91(1):59-62.
  207. Croonen H. Echt waar ? (verslag PHARMO symposium 10 november 2003). Pharm Weekblad. 2003:1741.
  208. Beiderbeck-Noll AB, Sturkenboom MC, van der Linden PD, Herings RM, Hofman A, Coebergh JW, et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer. 2003;39(1):98-105.
  209. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG. Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma. Am J Epidemiol. 2003;157(6):510-6.
  210. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324(7349):1306-7.
  211. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment. Eur J Clin Pharmacol. 2002;58(2):157-61.
  212. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol. 2002;54(2):168-70.
  213. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users. Acta Neurol Scand. 2002;105(1):8-12.
  214. Spoelstra JA, Stol RP, de Bruyne MC, Erkens JA, Herings RM, Leufkens HG, et al. Factors associated with switching from oral hypoglycaemic agents to insulin therapy. Neth J Med. 2002;60(6):243-8.
  215. Souverein PC, Herings RM, Man in 't Veld AJ, de la Rosette JJ, Farmer RD, Leufkens HG. Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia. Eur Urol. 2002;42(3):254-61.
  216. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Incidence and determinants of migraine prophylactic medication in the Netherlands. Eur J Clin Pharmacol. 2002;58(2):149-55.
  217. PHARMO. Kosten van geneesmiddelen in ziekenhuizen: Nu en in de toekomst. Utrecht: PHARMO Institute; 2002. 71 p.
  218. Movig KL, Leufkens HG, Lenderink AW, Egberts AC. Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly. Eur J Clin Pharmacol. 2002;58(2):143-8.
  219. Movig KL, Leufkens HG, Belitser SV, Lenderink AW, Egberts AC. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf. 2002;11(4):271-9.
  220. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius AJ, de Boer A. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol. 2002;53(4):379-85.
  221. Mantel-Teeuwisse AK, Klungel OH, Herings RM, van Puijenbroek EP, Porsius AJ, de Boer A. Myopathy due to statin/fibrate use in the Netherlands. Ann Pharmacother. 2002;36(12):1957-60.
  222. Herings RMC, Leufkens HGM, Heerdink ER, Klungel OH, Breekveldt-Postma NP. Chronic Pharmacotherapy Forever. Institute P, editor. Utrecht: PHARMO institute; 2002. 35 p.
  223. Herings RMC, Leufkens HGM, Heerdink ER, Klungel OH, Breekveldt-Postma NP. Chronische Farmacotherapie Voortgezet: Een haalbaarheidstudie naar de omvang, determinanten en economische consequenties van het vroegtijdig afbreken van chronische farmacotherapie. PHARMO-Institute, editor. Utrecht: PHARMO Institute; 2002 01-04-2001. 32 p.
  224. Herings RMC. Meer astma en COPD; beter behandeld. Pharm Weekblad. 2002;137(1):17-9.
  225. Herings RMC. Beslist voorgeschreven; Een achtergrond studie naar de omvang en kosten van poliklinisch voorgeschreven geneesmiddelen. Utrecht: PHARMO Instituut, 2002 Oktober. Report No.
  226. Erkens JA, Klungel OH, Herings RM, Stolk RP, Spoelstra JA, Grobbee DE, et al. Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. Eur Heart J. 2002;23(20):1575-9.
  227. Erkens JA, Herings RM, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Cardiovascular risk factors and diseases precede oral hypoglycaemic therapy in patients with type 2 diabetes mellitus. J Clin Epidemiol. 2002;55(4):345-9.
  228. De Bruin ML, Panneman MJ, Leufkens HG, Hoes AW, Herings RM. Use of cisapride with contraindicated drugs in The Netherlands. Ann Pharmacother. 2002;36(2):338-43.
  229. Breekveldt-Postma NS, Zwart-van Rijkom JE, Egberts AC, Leufkens HG, Herings RM. Stijgende kosten van geneesmiddelen in ziekenhuizen in 1996-2000 en in de komende jaren. Ned Tijdschr Geneeskd. 2002;146(52):2547-51. Stijgende kosten van geneesmiddelen in ziekenhuizen in 1996-2000 en in de komende jaren.
  230. Boermans PAMM, H.J. tH, B.H. G, Herings RMC. Nieuwe mogelijkheden voor farmaco-epidemiologisch onderzoek. Pharm Weekblad. 2002;137(46):1633-8.
  231. Westein MP, Herings RM, Leufkens HG. Determinants of pharmacists' interventions linked to prescription processing. Pharm World Sci. 2001;23(3):98-101.
  232. Vries CG, Herings RMC, De Jong van den Berg LTW. Informatiebronnen: Langs de valkuilen (4). Pharm Weekblad. 2001;136(32):1190-3.
  233. van der Linden PD, Nab HW, Simonian S, Stricker BH, Leufkens HG, Herings RM. Fluoroquinolone use and the change in incidence of tendon ruptures in The Netherlands. Pharm World Sci. 2001;23(3):89-92.
  234. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. Pharmacoepidemiol Drug Saf. 2001;10(6):549-54.
  235. Souverein PC, Herings RM, De la Rosette JJ, Man in 't Veld AJ, Farmer RD, Leufkens HG. Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. J Clin Epidemiol. 2001;54(5):518-24.
  236. Schillevoort I, de Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother. 2001;35(12):1517-22.
  237. Schillevoort I, de Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs. Eur J Clin Pharmacol. 2001;57(4):327-31.
  238. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol. 2001;54(11):1181-6.
  239. Jansen PA, Herings RM, Samson MM, De Vreede PL, Schuurmans-Daemen LM, Hovestadt A, et al. Quick titration of pergolide in cotreatment with domperidone is safe and effective. Clin Neuropharmacol. 2001;24(3):177-80.
  240. Herings RMC, Klungel OH. De kosten epidemiologisch benaderd. Pharm Weekblad. 2001;138(47):1771-3.
  241. Herings RMC. Doelmatigheid (editorial). Pharm Weekblad. 2001;136(15):521.
  242. Herings RMC. Ik benzo gevallen; benzodiazepinen in relatie tot (onge)vallen. Pharm Weekblad. 2001;136(49):1840-2.
  243. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID- induced gastrointestinal events in The Netherlands. Pharmacoeconomics. 2001;19(6):655-65.
  244. Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. Diabetes Care. 2001;24(8):1428-32.
  245. Bouvy ML, Herings RMC. Mothers little helper (editorial). Pharm Weekblad. 2001;136(49):1817.
  246. Bouvy ML, Heerdink ER, Herings RM. Long-term therapy with spironolactone. Pharm World Sci. 2001;23(4):132-4.
  247. van Eijk ME, Bahri P, Dekker G, Herings RM, Porsius A, Avorn J, et al. Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects. J Clin Epidemiol. 2000;53(6):645-51.
  248. van de Vijver D, Roos R, Jansen P, Porsius A, de Boer A. Start of antidepressant drugs in Parkinson's disease: association with the disease and its course. Int J Geriatric Psychopharmacol. 2000;2:148-52.
  249. Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A. Influence of question structure on the recall of self-reported drug use. J Clin Epidemiol. 2000;53(3):273-7.
  250. Herings RMC, Panneman MJM, de Graag EJ. Farmacotherapie in beweging. Utrecht: PHARMO Instituut; 2000 Februari 2000. 55 p.
  251. Herings RMC, Panneman MJM, de Graag EJ. Innovations in pharmacotherapy. Utrecht: PHARMO Institute; 2000 Februari 2000. 55 p.
  252. Herings RMC. Interventies (editorial). Pharm Weekblad. 2000;138(28):1009.
  253. Herings RMC. Astrononsens (editorial). Pharm Weekblad. 2000;135(45):1657.
  254. Herings RM, Leufkens HG, Vandenbroucke JP. Acute myocardial infarction and prior antibiotic use. JAMA : the journal of the American Medical Association. 2000;284(23):2998-9.
  255. Burger H, Herings RM, Egberts AC, Neef C, Leufkens HG. Cyclical etidronate use is not associated with symptoms of peptic ulcer disease. Eur J Clin Pharmacol. 2000;56(4):319-22.
  256. Bouvy ML, Heerdink ER, De Bruin ML, Herings RM, Leufkens HG, Hoes AW. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med. 2000;160(16):2477-80.
  257. van der Klauw MM, Goudsmit R, Halie MR, van't Veer MB, Herings RM, Wilson JH, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med. 1999;159(4):369-74.
  258. Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A. Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci. 1999;21(5):217-20.
  259. Herings RMC. De doelmatige rol van de farmaco-epidemiologie (editorial). Pharm Weekblad. 1999;134(5):145.
  260. Herings RMC. De schade van het schijnargument (editorial). Pharm Weekblad. 1999;134(20):685.
  261. Herings RMC. De illusie van kennis is schadelijker dan onwetenheid. Pharm Weekblad. 1999;134(5):162-6.
  262. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives [letter] [see comments]. Lancet. 1999;354(9173):127-8.
  263. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives (including erratum). Lancet. 1999;354(9173):127-8.
  264. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. Asthma exacerbations during first therapy with long acting beta 2-agonists. Pharm World Sci. 1999;21(3):116-9.
  265. Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis. 1998;17(1):20-4.
  266. Herings RMC, Leufkens HGM. Community Pharmacy Networks in Pharmacoepidemiology. In: Hartzema AG, Porta M, Tilson HH, editors. Pharmacoepidemiology: An introduction. Third Edition ed. Cincinnatti, USA: Harvey Whitney Books; 1998. p. 405-20.
  267. Herings RMC. Van ‘data-mining’ tot ‘data-minding’ (editorial). Pharm Weekblad. 1998;133(29):1069.
  268. Herings RMC. Absinthsiroop terug in het land (editorial). Pharm Weekblad. 1998;133(2):57.
  269. Herings RMC. Ademnood (redactioneel). Pharm Weekblad. 1998:397.
  270. Herings RMC. Wat er mis kan gaan, leren we in de praktijk. Pharm Weekblad. 1998;133(49):1833-6.
  271. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158(10):1108-12.
  272. van Riemsdijk MM, van der Klauw MM, van Heest JA, Reedeker FR, Ligthelm RJ, Herings RM, et al. Neuro-psychiatric effects of antimalarials. Eur J Clin Pharmacol. 1997;52(1):1-6.
  273. Jury-rapport betreffende de uitreiking van de 5de Hoogendoornprijs, (1997).
  274. Shackleton DP, Westendorp RG, Kasteleijn-Nolst Trenite DG, de Boer A, Herings RM. Dispensing epilepsy medication: a method of determining the frequency of symptomatic individuals with seizures. J Clin Epidemiol. 1997;50(9):1061-8.
  275. Ooms P. Dr Ron Herings wint Hoogendoornprijs. Signet. 1997:5-8.
  276. Herings RMC. Medicatiebewaking gebaat bij samenwerking. Pharm Weekblad. 1997;132(30):1030-3.
  277. Willigenburg APP, Franssen EAM, Lebret E, Herings RMC. Geneesmiddelengebruik als indicator voor de effecten van milieuverontreiniging. Een studie in de regio Schiphol. Utrecht
  278. Bilthoven: Universiteit Utrecht
  279. RIVM; 1996. 112 p.
  280. Lammers MW, Hekster YA, Keyser A, Meinardi H, Renier WO, Herings RM. Use of antiepileptic drugs in a community-dwelling Dutch population. Neurology. 1996;46(1):62-7.
  281. Herings RMC, Leufkens HGM. Veiligheid derde generatie orale anticonceptiva. Conceptuur. 1996;8:7-8.
  282. Herings RMC, de Boer A, B.H.Ch. S, Leufkens HGM, Porsius AJ. ACE-remmers vergroten het risico op hypoglykemie bij diabetici. Ned Tijdschr Geneeskd. 1996;140(8):432-36.
  283. Herings RMC. Rapid Response to drug alerts. In: Lewis MA, Meyer R, Dopfmer A, Guggenmoos-Holzmann I, editors. Rapid Response Unit: Moglichkeiten und bedraf der Pharmakoepidemiologie in Deutschland. Berlin: Freie Universitaet Berlin; 1996. p. 11-9.
  284. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F, Stergachis A. Current use of thiazide diuretics and prevention of femur fractures. J-Clin-Epidemiol. 1996;49(1):115-9 issn: 0895-4356.
  285. van Riemsdijk MM, Herings RM, Rawlins MD, Stricker BH. Redenen om wel of niet bijwerkingen van geneesmiddelen te melden bij het landelijke meldingssysteem in Nederland. Ned Tijdschr Geneeskd. 1995;139(45):2306-8. Redenen om wel of niet bijwerkingen van geneesmiddelen te melden bij het landelijke meldingssysteem in Nederland.
  286. Van Ganse E, van der Linden PD, Leufkens HG, Herings RM, Vincken W, Ernst P. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J. 1995;8(11):1856-60.
  287. Herings RMC, de Boer A, Bakker A, Stricker BHC, Sturmans F. Femurfracturen, vallen en het gebruik van benzodiazepines: dosering belangrijker dan eliminatiehalfwaardetijd. Ned Tijdsch Farmacotherapie. 1995;1:2-9.
  288. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995;155(16):1801-7.
  289. Herings RM, Stricker BH. Bromocriptine and suppression of postpartum lactation. The incidence of adverse cardiovascular effects in women of child-bearing age. Pharm World Sci. 1995;17(4):133-7.
  290. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995;345(8959):1195-8.
  291. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Comments: Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995;345(8959):125-7.
  292. Herings RM, de Boer A, Stricker BH, Bakker A, Sturmans F. A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age. Pharm-World-Sci. 1995;17(1):17-9.
  293. Brok M. Vermijdbare narigheid. Trefpunt. 1995:18-9.
  294. van Riemsdijk MM, M. vdKM, Stricker BHC, Herings RMC. Huidreacties toegeschreven aan het gebruik van broomhexine. Ned Tijdschr Geneeskd. 1994;138(49):2446-8.
  295. Van der Klauw MM, Stricker BHC, Herings RMC, Cost WS, Valkenburg HA, Wilson JHP. Ziekenhuisopname in Nederland vanwege anaphylaxie door glafenine, 1987-1988. Ned Tijdschr Geneeskd. 1994;138(3):140-4.
  296. Leufkens HG, Herings RM, Urquhart J. Efficacy of low-density-lipoprotein lowering with statins. Lancet. 1994;344(8923):683-4.
  297. Herings RMC. Geneesmiddelen als determinant van ongevallen. Utrecht: University Utrecht, 1994 90-393-0876-4.
  298. van der Klauw MM, Stricker BH, Herings RM, Cost WS, Valkenburg HA, Wilson JH. A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol. 1993;35(4):400-8.
  299. Herings RMC, Heerdink ER, Bakker A. Ouderen en gecombineerd gebruik van geneesmiddelen. Pharmaceutisch Weekblad. 1993;128(49):1498-500.
  300. Herings RMC. PHARMO: A record linkage system for postmarketing surveillance of prescription drugs in the Netherlands [Doctorate]. Utrecht: Utrecht University; 1993.
  301. Herings RM, Stricker BH, Leufkens HG, Bakker A, Sturmans F, Urquhart J. Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands. Pharm World Sci. 1993;15(5):212-8.
  302. de Boer A, Herings RM. Oral contraceptives without prescription. Lancet. 1993;342(8877):993.
  303. Stricker BH, Barendregt M, Herings RM, de Jong-van den Berg LT, Cornel MC, de Smet PA. Ad hoc tracing of a cohort of patients exposed to acitretine (Neotigason) on a nation-wide scale. Eur J Clin Pharmacol. 1992;42(5):555-7.
  304. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992;46(2):136-40.
  305. Stricker BH, Barendregt M, Herings RM, de Jong-van den Berg LT, Cornel MC, de Smet PA. [Acitretin; an example of ad-hoc tracing of users in acute problems with drugs]. Ned Tijdschr Geneeskd. 1991;135(21):934-7.
  306. Petri H, Uruqhart J, Herings RMC, Bakker A. Characteristics of patients prescribed two different: an example of the channeling phenomene beta-2 agonists. Postmarketiijk Surveillance. 1991;5(157-65).
  307. Leufkens HGM, Herings RMC, Kollofel WJ, Bakker A. Concomitant drug use among patients on cardiac glycosides. Int J Risk Saf Med. 1991;2:11-20.
  308. Herings RMC. Patterns of long term drug use in the Netherlands. In: Bakker A, Hekster YA, Leufkens HGM, editors. Drug consumption in the Netherlands. Noordwijk: Amsterdam Medical Press; 1991. p. 50-8.
  309. Stricker BHC, Herings RMC, Bakker A, Valkenburg HA, Sturmans F. Farmacomorbidteitskoppeling:een potentieel instrument voor 'post marketing surveillance'. Ned Tijdschr Geneeskd. 1990;134(39):1886-9.
  310. Leufkens HGM, Luinge A, Herings RMC, Bakker A. Grafische presentatie van medicatiepatronen. Pharm Weekbld. 1990;125(1):4-8.
  311. Herings RMC, Stricker BHC, Bakker A. Farmacomorbiditeitskoppeling:een orienterende studie naar de technische mogelijkheden in Nederland. Ned Tijdschr Geneeskd. 1990;134(7):1903-7.
  312. Herings RMC, Stricker BHC, van Romnde L, Bakker A. Validation of record linkage based on characteristics of patients: A Pilot study in the Netherlands. In: Muller NF, Hekster YA, editors. Rational use of drugs. Noordwijk: Amsterdam Medical Press; 1989. p. 235-55.
  313. Herings RMC. Effecten van chronisch en gecombineerd gebruik van geneesmiddelen. Utrecht: Utrecht University, 1988.